^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
AB-205
i
Other names: AB-205, E-CEL UVEC
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Angiocrine
Drug class:
Cell replacement
Related drugs:
4ms
E-CEL UVEC Treatment for Anal Fissures (clinicaltrials.gov)
P1, N=12, Recruiting, Weill Medical College of Cornell University | Not yet recruiting --> Recruiting
Enrollment open
|
AB-205
5ms
E-CEL UVEC Treatment for Anal Fissures (clinicaltrials.gov)
P1, N=12, Not yet recruiting, Weill Medical College of Cornell University
New P1 trial
|
AB-205
6ms
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas (clinicaltrials.gov)
P1, N=33, Recruiting, Weill Medical College of Cornell University | Phase classification: P1b --> P1 | N=12 --> 33 | Trial completion date: Dec 2031 --> Jun 2032 | Trial primary completion date: Dec 2024 --> Sep 2025
Phase classification • Enrollment change • Trial completion date • Trial primary completion date
|
AB-205
10ms
E-CELERATE: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation (clinicaltrials.gov)
P3, N=130, Terminated, Angiocrine Bioscience | Trial completion date: Dec 2025 --> Jan 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Dec 2023; Interim analysis showed lack of efficacy
Trial completion date • Trial termination • Trial primary completion date
|
AB-205
11ms
E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults (clinicaltrials.gov)
P1, N=20, Active, not recruiting, Hospital for Special Surgery, New York
Trial completion date • Trial primary completion date
|
AB-205
4years
[VIRTUAL] Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (ASH 2020)
AB-205 appears to be safe and potentially effective in subjects undergoing HDT-AHCT for lymphoma. Compared to published rates of 24-41% for G ≥3 OM (Singer 2019; Colita 2109) and 86% for FN (Caimi 2105) in subjects with systemic lymphoma, we observed 0% SRRT and 31% FN with the highest dose of AB-205 tested. AB-205 has significant potential to address a serious unmet medical need in patients undergoing HDT-AHCT and will be assessed in a forthcoming pivotal, double-blinded, placebo-controlled, randomized clinical trial for potential registration.
Clinical • P1 data
|
CD34 (CD34 molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1)
|
AB-205
Share via
